Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Innate Immunity

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1753425908099173PMID 19039062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endogenous cortisol determines the circadian rhythm of lipopolysaccharide‐ but not lipoteichoic acid‐inducible cytokine release

  2006cited by this paper
• TLR4 antagonists for endotoxemia and beyond.

  2005cited by this paper
• Pharmacological Inhibition of Endotoxin Responses Is Achieved by Targeting the TLR4 Coreceptor, MD-21

  2005cited by this paper
• Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia

  2004cited by this paper
• Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

  2004cited by this paper
• Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin Antagonist

  2003cited by this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of E5564, a Lipid A Antagonist, during an Ascending Single‐Dose Clinical Study

  2003cited by this paper
• Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.

  2003cited by this paper
• Lipopolysaccharide Interaction with Cell Surface Toll-like Receptor 4-MD-2

  2003cited by this paper
• Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

  2002cited by this paper
• Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

  2000cited by this paper
• Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

  1999cited by this paper
• Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor.

  1999cited by this paper
• Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

  1998cited by this paper
• Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs

  1995cited by this paper
• Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models.

  1995cited by this paper
• The role of lipoproteins in the inactivation of endotoxin by serum.

  1992cited by this paper

• An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases

  2024cites this paper
• Decrease in the inflammatory cytokines of LPS-stimulated PBMCs of patients with atherosclerosis by a TLR-4 antagonist in the co-culture with HUVECs.

  2021cites this paper
• Immunotherapy in sepsis - brake or accelerate?

  2020cites this paper
• Targeting toll-like receptor-4 (TLR4)—an emerging therapeutic target for persistent pain states

  2018cites this paper
• Mechanisms of complement activation under hemolytic conditions

  2017cites this paper
• TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis

  2017cites this paper
• Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling.

  2017cites this paper
• Host defenses against metabolic endotoxaemia and their impact on lipopolysaccharide detection

  2017cites this paper
• Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics

  2017cites this paper
• The Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial Disease

  2016cites this paper
• Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases

  2013cites this paper
• Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria

  2013cites this paper
• Therapeutic Strategies to Treat Alcohol-Related Disorders Targeting Central Immune Signaling

  2013cites this paper
• Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men

  2012cites this paper
• Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.

  2011cites this paper
• Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

  2011cites this paper
• Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

  2011influential citation
• Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling

  2010cites this paper
• Deactivation of the LPS antagonist eritoran by HDL-associated apolipoproteins

  2010cites this paper
• Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis

  2010cites this paper
• Regulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders.

  2009cites this paper
• Pattern Recognition Receptor–Dependent Mechanisms of Acute Lung Injury

  2009cites this paper